证券日报网讯葵花药业9月25日在互动平台回答投资者提问时表示，公司目前产品以中成药为主，未来 将通过"买、改、联、研"等多维渠道扩大产品覆盖，完善品类布局。 （文章来源：证券日报） ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]

证券代码：002737 证券简称：葵花药业 公告编号：2025-058 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议、第五届监事会第四次会议、公司 2024 年年度股东大会审议通过，公司决定 使用闲置自有资金额度不超过 20 亿元人民币进行现金管理，上述额度自股东大 会审议通过之日起 12 个月内有效，有效期内，上述额度可滚存使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《上海证券报》、《证券日报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 140,000 万元购买了部分理财 产品，具体情况如下： | 4 | 中国银行 哈尔滨香 | （机构专属）中银理 财-睿享（封闭式） | 固定收益类 非保本浮动 | 60,000.00 | ...

Group 1 - The core point of the article is that Kewang Pharmaceutical (002737) reported a total of 55,000 shareholders as of the end of August [1]

Group 1 - The company has received the drug registration certificate for Desloratadine Oral Suspension from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - The drug is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children aged 2 and above, and chronic idiopathic urticaria in children aged 6 months and above [2][3] - The product is classified as a prescription drug and falls under the category of Class 3 chemical drugs, with a specification of 120ml containing 0.72g of the active ingredient Desloratadine [6][4] Group 2 - The approval of Desloratadine Oral Suspension will help the company expand its product pipeline and enhance its therapeutic area coverage [4] - The company plans to strengthen quality and process control during the product's subsequent mass production and market launch [4] - The drug registration number for Desloratadine is H20255183, and the manufacturing entity is Chongqing Little Sunflower Children's Pharmaceutical Co., Ltd., a subsidiary of the company [6][4]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its oral suspension of Fexofenadine Hydrochloride [2] Group 2 - The approval of the drug registration indicates a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry, particularly in allergy treatment [2] - The registration could lead to increased revenue opportunities for Kew Flower Pharmaceutical as it introduces the new product to the market [2]

Core Viewpoint - The approval of the oral suspension of Fexofenadine Hydrochloride by the National Medical Products Administration will enhance the company's product pipeline and therapeutic coverage in the allergy treatment sector [1] Group 1 - The company has received a drug registration certificate for Fexofenadine Hydrochloride oral suspension [1] - This product is aimed at the allergy treatment market, indicating a strategic expansion in the company's offerings [1] - The company plans to accelerate the mass production and market launch of this product, facilitating the rapid conversion of research outcomes into marketable products [1]

格隆汇9月1日丨葵花药业(002737.SZ)公布，公司子公司于近日收到国家药品监督管理局下发的关于盐 酸非索非那定口服混悬液获批注册的药品注册证书。盐酸非索非那定口服混悬液应用于抗过敏领域，该 产品的获批将有助于公司拓展产品管线、完善品类布局、提升治疗领域覆盖，公司将加速推进产品的后 续量产上市，实现研发成果快速转化。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's drug, a hydrochloride formulation of fexofenadine oral suspension, which is now registered as a prescription medication [1] Group 1: Drug Approval Details - The drug is classified as a Class 3 chemical drug and is intended for the relief of seasonal allergic rhinitis symptoms in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1] - The registered specification of the drug is 120ml containing 0.72g of the active ingredient [1]

Group 1 - The company announced that its subsidiary has received a drug registration certificate from the National Medical Products Administration for the oral suspension of Fexofenadine Hydrochloride [1] - The drug is classified as a Class 3 chemical drug and is a prescription medication [1] - The approved specifications for the drug are 120ml:0.72g, and it is indicated for alleviating symptoms of seasonal allergic rhinitis in children aged 2 years and older, as well as chronic idiopathic urticaria skin symptoms in children aged 6 months and older [1]